Deploying myeloid cells against myeloma

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Multiple myeloma remains an incurable cancer despite advances in treatment.
• Minimal residual disease (MRD) is a key factor in relapse after therapy.
• Myeloid cells, particularly macrophages, play complex roles in the tumor microenvironment.

Purpose of the Study:

• To explore the potential of reprogramming myeloid cells to control minimal residual disease in multiple myeloma.
• To review macrophage-myeloma cell interactions and therapeutic reprogramming strategies.

Main Methods:

• Review of existing literature from our laboratory and others.
• Analysis of macrophage-myeloma cell crosstalk mechanisms.
• Evaluation of strategies for therapeutic macrophage reprogramming.

Main Results:

• Macrophage-myeloma cell interactions can be modulated.
• Therapeutic reprogramming of macrophages offers a potential strategy for controlling residual myeloma.

Conclusions:

• Reprogramming myeloid cells to exhibit tumoricidal activity presents a novel therapeutic avenue for managing minimal residual disease in multiple myeloma.
• Targeting macrophage-myeloma cell crosstalk is crucial for developing effective treatments against incurable myeloma.